The number of musk deer in Mongolia has plummeted by some 83 per cent since the 1970s, landing them on the country’s red list of critically endangered species. A UN-supported biodiversity initiative is helping to stop the deer from disappearing altogether.
After vowing to retaliate against Lithuania’s move to allow Taiwan open a “representative office” in Vilnius, Beijing has announced it is downgrading diplomatic relations with the Baltic state.
In a statement on Sunday, the Chinese foreign ministry said that China’s diplomatic relations with Lithuania will be formally lowered to the level of charge d’affaires, while blasting Vilnius for setting a “bad international precedent” by giving the island the green light to open its mission in the Lithuanian capital.
The ministry went on to accuse Vilnius of undermining the One China principle and the principle of neutrality in bilateral relations, explaining its decision to demote relations by citing the need to “safeguard its sovereignty and the basic norms of international relations.”
“The Lithuanian government must bear all the consequences arising from this,” the ministry said, while calling on Vilnius to “correct its mistakes immediately.”
“No matter how the ‘Taiwan independence’ forces distort facts and reverse black and white, they cannot change the historical fact that the mainland and Taiwan belong to the same China,” the ministry asserted.
The move comes just two days after Beijing went on a verbal offensive against the Baltic country, warning that pushback for its cozying up to Taiwan would be imminent. “As to what necessary measures China will take, you may wait and see,” it said at the time.
Lithuania and China have been embroiled in a diplomatic row and have not maintained relations at ambassadorial level since September. After the Baltic state revealed that it would be opening a de facto Taiwanese embassy, China withdrew its ambassador from the country in August. Vilnius followed suit the following month.
Think your friends would be interested? Share this story!
After vowing to retaliate against Lithuania’s move to allow Taiwan open a “representative office” in Vilnius, Beijing has announced it is downgrading diplomatic relations with the Baltic state.
In a statement on Sunday, the Chinese foreign ministry said that China’s diplomatic relations with Lithuania will be formally lowered to the level of charge d’affaires, while blasting Vilnius for setting a “bad international precedent” by giving the island the green light to open its mission in the Lithuanian capital.
The ministry went on to accuse Vilnius of undermining the One China principle and the principle of neutrality in bilateral relations, explaining its decision to demote relations by citing the need to “safeguard its sovereignty and the basic norms of international relations.”
“The Lithuanian government must bear all the consequences arising from this,” the ministry said, while calling on Vilnius to “correct its mistakes immediately.”
“No matter how the ‘Taiwan independence’ forces distort facts and reverse black and white, they cannot change the historical fact that the mainland and Taiwan belong to the same China,” the ministry asserted.
The move comes just two days after Beijing went on a verbal offensive against the Baltic country, warning that pushback for its cozying up to Taiwan would be imminent. “As to what necessary measures China will take, you may wait and see,” it said at the time.
Lithuania and China have been embroiled in a diplomatic row and have not maintained relations at ambassadorial level since September. After the Baltic state revealed that it would be opening a de facto Taiwanese embassy, China withdrew its ambassador from the country in August. Vilnius followed suit the following month.
Think your friends would be interested? Share this story!
A gunman injured two civilians, one of them fatally, and two police officers before being shot dead by security forces near Jerusalem’s Western Wall on Sunday morning, Israeli police said.
The civilian victims were taken to Shaare Zedek Medical Center. One, who was in his 30s, succumbed to his injuries at the hospital. The other, a 46-year-old, is said to have suffered moderate injuries. Two police officers were hurt by shrapnel.
Two civilians were critically and seriously wounded this morning, Sunday, and two policemen were lightly wounded in a shooting attack in the area of the Chain Gate near the Western Wall and the entrance to the Temple Mount. pic.twitter.com/MRN6MLckj3
In a video clip shared on social media and purportedly filmed at the scene, multiple gunshots could be heard amid agitated shouting. Security officers could then be seen standing around what appears to be a dead body. Witnesses speculated it was that of a “terrorist.”
Scenes and sounds of shooting in the Old City of Jerusalem captured on Live Cam. Initial reports are attack is near the Temple Mount area 2 Israelis wounded one apparently seriously the terrorist has been neutralised pic.twitter.com/UKWSOqCu8D
— ElBluemountain MossadDolphin 🇮🇱🐬🇮🇱🐬🇮🇱 (@EBluemountain1) November 21, 2021
The gunman, whose identity was not immediately disclosed, was killed during the incident. Police said he had used a homemade submachine gun.
A gunman injured two civilians, one of them fatally, and two police officers before being shot dead by security forces near Jerusalem’s Western Wall on Sunday morning, Israeli police said.
The civilian victims were taken to Shaare Zedek Medical Center. One, who was in his 30s, succumbed to his injuries at the hospital. The other, a 46-year-old, is said to have suffered moderate injuries. Two police officers were hurt by shrapnel.
Two civilians were critically and seriously wounded this morning, Sunday, and two policemen were lightly wounded in a shooting attack in the area of the Chain Gate near the Western Wall and the entrance to the Temple Mount. pic.twitter.com/MRN6MLckj3
In a video clip shared on social media and purportedly filmed at the scene, multiple gunshots could be heard amid agitated shouting. Security officers could then be seen standing around what appears to be a dead body. Witnesses speculated it was that of a “terrorist.”
Scenes and sounds of shooting in the Old City of Jerusalem captured on Live Cam. Initial reports are attack is near the Temple Mount area 2 Israelis wounded one apparently seriously the terrorist has been neutralised pic.twitter.com/UKWSOqCu8D
— ElBluemountain MossadDolphin 🇮🇱🐬🇮🇱🐬🇮🇱 (@EBluemountain1) November 21, 2021
The gunman, whose identity was not immediately disclosed, was killed during the incident. Police said he had used a homemade submachine gun.
As infections are rising again, scientists all around the world are rushing to fight the danger, offering a choice of new treatments and unusual variants of vaccines.
Levels of contagion are setting new records, hospitals are overwhelmed, governments are starting to introduce lockdowns, and not only for unvaccinated people – the picture of the fight against Covid-19 looks quite disappointing. However, there’s still a place for good news: Research teams report positive results while trialling new medicines and vaccine types.
Nasal vaccines
Vaccination will remain one of the most effective tools against Covid-19. As Professor David Dockrell, from the Center for Inflammation Research of the University of Edinburgh, told RT, “vaccines will continue to be a central part of how we control the virus.”
“If we can dampen down the number of infections, and the severity of infections, and also the extent to which the virus can replicate in people when they become infected, then we are slowing down the ability of the virus to change and to mutate,” he explains.
So I think the vaccines still will be a very important part of the preventive strategy. It’s vital that they are available to all the world’s population, irrespective of where people live, and the wealth of the country in which they live.
However, vaccination doesn’t always mean you have to get an injection. For instance, several intranasal Covid-19 vaccines are currently being developed. As the virus gets into the body through the nose, a nasal spray or drops are aimed to produce mucosal immune response and prevent it from getting into the lungs.
In India, a vaccine of this type is already completing Phase 2 of clinical trials. In Russia, a nasal vaccine is undergoing a clinical trial on volunteers. In Thailand, a home-developed product is expected to be trialed on humans next spring. In the US, Universities of Houston and Stanford recently reported good results of their experiments carried out on mice.
Intranasal vaccines can have several potential benefits compared to inoculation.
“They would be easier to use, because they can be self-administered. They wouldn’t need a nurse or clinical settings,” Swedish professor emeritus of epidemiology Marcello Ferrada de Noli explained to RT. As a result, he says, there’s hope that fewer people will be reluctant to be immunized. Not so many of us find it pleasant to get a jab – and after all, there are those who are just afraid of needles. Also, it would be much easier to vaccinate children with nasal substances.
However, what concerns Prof. de Noli the most is the duration of the effect of a vaccine of this type. Still, scientists can’t say for sure whether a nasal substance may completely replace a shot. According to Alexander Gintsburg, the head of Moscow’s Gamaleya Center biomedical research institute, which created the Sputnik V vaccine, the nasal version they are working on would serve for an additional protection against the virus, but would not replace the injections.
Chew the virus away?
A nasal vaccine is not the only one being developed. In summer, it was revealed that Russian Defense Ministry scientists were creating a ‘chewing gum’ vaccine, also targeting the mucosal immune response. Meanwhile, a UK firm announced this month that it would conduct a human trial of a skin patch that uses T-cells to confront the virus. Developers hope it would offer longer-lasting immunity than the existing vaccines. Work on a similar project is being done in the University of Queensland, Australia.
While it all looks so promising, Prof. de Noli warns that it would still take a lot of time until these products become available to the public. “I think that discoveries in this field are a very good thing. But if we say ‘We discovered a new type of vaccine’, people will say ‘Aha, so I’m going to wait’. But we need to vaccinate people now,” he points out.
Improving Covid treatment
Vaccines are not a silver bullet, unfortunately, given the not-so-high level of global immunization and the constantly emerging new strains of the virus. “People might get infected despite having had a vaccine, but I still think the vaccine strategy is going to be central to how we manage this kind of virus going forward,” Prof. Dockrell says. “But we will have other strategies that will be very important. We will have other elements. When we put them all together, it gives us the best opportunity that people can live with coronaviruses, and hopefully, the mortality can be limited to much lower extense than what we’ve sadly seen in the last eighteen months.”
Monoclonal antibodies will be central to the ongoing vaccine strategy, Prof. Dockrell explains. These are the antibodies similar to those the body uses to fight the virus. They are produced in labs and given via infusion or injection to boost the patient’s response against certain diseases. Monoclonal antibody treatment is used for people under a high risk of developing severe infection (including older patients 65+ years old or those with chronic medical conditions). It’s already being used in the US, following last year’s FDA approval. Earlier in November, the European Medicines agency recommended authorizing two monoclonal antibody medicines.
In October, UK’s AstraZeneca reported positive results of a Phase 3 study of its antibody combination, which, according to developers, is highly effective in both prevention and treatment of coronavirus.
Researchers are also working on a possibility to save Covid-infected patients from the so-called ‘cytokine storm’ – a situation when the immune system reacts so intensely that kills not only the virus, but the whole organism itself. A drug to ‘calm the storm’ was registered in Russia this year, and it’s already being used on patients.
Another way to fight Covid-19 is to use antiviral drugs. When the pandemic started, medics had to use something already existing (like anti-influenza Favipiravir) or something being authorized for emergency use (like remdesivir). Now, more than a year on, the work to create a special drug to specifically cure Covid-19 is giving its results. This month, Russia registered its first injectable anti-Covid medicine. A bit earlier, the UK became the first country to approve an antiviral pill produced by the US-based companies Merck and Ridgeback Biotherapeutics. Another American firm, Pfizer, got positive results from trials of its drug of the same kind. Both firms hope that with a drug in the form of a pill it would be easier to treat people at home.
Appreciating all the efforts on the field of developing anti-Covid treatment, Prof. de Noli points out that still, the key issue now is to reduce the spreading of the virus. “The new medicines are developed for people who already got the disease,” he says.
But we need to prevent people from getting the infection, not let them get infected because we have some new medicine that can cure them.
The same idea is echoed by scientists all over the world quoted in plenty of articles dedicated to the medical gains: it’s great to have the treatment, but none of the drugs may substitute vaccination, as first and foremost, humanity has to adopt preventive measures and stop the pandemic.
As infections are rising again, scientists all around the world are rushing to fight the danger, offering a choice of new treatments and unusual variants of vaccines.
Levels of contagion are setting new records, hospitals are overwhelmed, governments are starting to introduce lockdowns, and not only for unvaccinated people – the picture of the fight against Covid-19 looks quite disappointing. However, there’s still a place for good news: Research teams report positive results while trialling new medicines and vaccine types.
Nasal vaccines
Vaccination will remain one of the most effective tools against Covid-19. As Professor David Dockrell, from the Center for Inflammation Research of the University of Edinburgh, told RT, “vaccines will continue to be a central part of how we control the virus.”
“If we can dampen down the number of infections, and the severity of infections, and also the extent to which the virus can replicate in people when they become infected, then we are slowing down the ability of the virus to change and to mutate,” he explains.
So I think the vaccines still will be a very important part of the preventive strategy. It’s vital that they are available to all the world’s population, irrespective of where people live, and the wealth of the country in which they live.
However, vaccination doesn’t always mean you have to get an injection. For instance, several intranasal Covid-19 vaccines are currently being developed. As the virus gets into the body through the nose, a nasal spray or drops are aimed to produce mucosal immune response and prevent it from getting into the lungs.
In India, a vaccine of this type is already completing Phase 2 of clinical trials. In Russia, a nasal vaccine is undergoing a clinical trial on volunteers. In Thailand, a home-developed product is expected to be trialed on humans next spring. In the US, Universities of Houston and Stanford recently reported good results of their experiments carried out on mice.
Intranasal vaccines can have several potential benefits compared to inoculation.
“They would be easier to use, because they can be self-administered. They wouldn’t need a nurse or clinical settings,” Swedish professor emeritus of epidemiology Marcello Ferrada de Noli explained to RT. As a result, he says, there’s hope that fewer people will be reluctant to be immunized. Not so many of us find it pleasant to get a jab – and after all, there are those who are just afraid of needles. Also, it would be much easier to vaccinate children with nasal substances.
However, what concerns Prof. de Noli the most is the duration of the effect of a vaccine of this type. Still, scientists can’t say for sure whether a nasal substance may completely replace a shot. According to Alexander Gintsburg, the head of Moscow’s Gamaleya Center biomedical research institute, which created the Sputnik V vaccine, the nasal version they are working on would serve for an additional protection against the virus, but would not replace the injections.
Chew the virus away?
A nasal vaccine is not the only one being developed. In summer, it was revealed that Russian Defense Ministry scientists were creating a ‘chewing gum’ vaccine, also targeting the mucosal immune response. Meanwhile, a UK firm announced this month that it would conduct a human trial of a skin patch that uses T-cells to confront the virus. Developers hope it would offer longer-lasting immunity than the existing vaccines. Work on a similar project is being done in the University of Queensland, Australia.
While it all looks so promising, Prof. de Noli warns that it would still take a lot of time until these products become available to the public. “I think that discoveries in this field are a very good thing. But if we say ‘We discovered a new type of vaccine’, people will say ‘Aha, so I’m going to wait’. But we need to vaccinate people now,” he points out.
Improving Covid treatment
Vaccines are not a silver bullet, unfortunately, given the not-so-high level of global immunization and the constantly emerging new strains of the virus. “People might get infected despite having had a vaccine, but I still think the vaccine strategy is going to be central to how we manage this kind of virus going forward,” Prof. Dockrell says. “But we will have other strategies that will be very important. We will have other elements. When we put them all together, it gives us the best opportunity that people can live with coronaviruses, and hopefully, the mortality can be limited to much lower extense than what we’ve sadly seen in the last eighteen months.”
Monoclonal antibodies will be central to the ongoing vaccine strategy, Prof. Dockrell explains. These are the antibodies similar to those the body uses to fight the virus. They are produced in labs and given via infusion or injection to boost the patient’s response against certain diseases. Monoclonal antibody treatment is used for people under a high risk of developing severe infection (including older patients 65+ years old or those with chronic medical conditions). It’s already being used in the US, following last year’s FDA approval. Earlier in November, the European Medicines agency recommended authorizing two monoclonal antibody medicines.
In October, UK’s AstraZeneca reported positive results of a Phase 3 study of its antibody combination, which, according to developers, is highly effective in both prevention and treatment of coronavirus.
Researchers are also working on a possibility to save Covid-infected patients from the so-called ‘cytokine storm’ – a situation when the immune system reacts so intensely that kills not only the virus, but the whole organism itself. A drug to ‘calm the storm’ was registered in Russia this year, and it’s already being used on patients.
Another way to fight Covid-19 is to use antiviral drugs. When the pandemic started, medics had to use something already existing (like anti-influenza Favipiravir) or something being authorized for emergency use (like remdesivir). Now, more than a year on, the work to create a special drug to specifically cure Covid-19 is giving its results. This month, Russia registered its first injectable anti-Covid medicine. A bit earlier, the UK became the first country to approve an antiviral pill produced by the US-based companies Merck and Ridgeback Biotherapeutics. Another American firm, Pfizer, got positive results from trials of its drug of the same kind. Both firms hope that with a drug in the form of a pill it would be easier to treat people at home.
Appreciating all the efforts on the field of developing anti-Covid treatment, Prof. de Noli points out that still, the key issue now is to reduce the spreading of the virus. “The new medicines are developed for people who already got the disease,” he says.
But we need to prevent people from getting the infection, not let them get infected because we have some new medicine that can cure them.
The same idea is echoed by scientists all over the world quoted in plenty of articles dedicated to the medical gains: it’s great to have the treatment, but none of the drugs may substitute vaccination, as first and foremost, humanity has to adopt preventive measures and stop the pandemic.
Japan’s fifth wave of Covid-19 has virtually disappeared so dramatically that some scientists are puzzled as to why it happened. One team suggests the highly infectious Delta strain mutated into extinction on the island nation.
In mid-August, Japan experienced a peak in Covid-19 infections, recording over 23,000 new cases per day. Now the metric is just around 170, with deaths attributed to the disease mostly remaining in single digits this month.
The decline has been attributed by many to high vaccination rates, public acceptance of masks, and other factors, but some researchers say the drop was uniquely significant, compared to other nations with similar conditions.
Ituro Inoue, a geneticist at the National Institute of Genetics, believes that Japan had the good fortune of witnessing the Delta strain mostly rooting out other variants of the SARS-CoV-2 virus before then eradicating itself. He explained his team’s theory to the Japan Times newspaper this week.
For some time now, Inoue and his fellow scientists were researching mutations of SARS-CoV-2 and how they are affected by the protein nsp14, which is crucial for the reproduction of the virus.
RNA viruses, like the one causing Covid-19, tend to have a very high mutation rate, which helps them quickly adapt to changes in the environment. However, this opens the door for a so-called “error catastrophe,” when bad mutations pile up and finally cause the full extinction of a strain. The protein nsp14 appears to offer a form of error proofreading that helps the virus genome to stay below the threshold of the “error catastrophe.”
In the case of Japan’s fifth wave of Covid-19, the Delta variant’s nsp14 failed at this job, Inoue believes, based on the genetic study of specimens collected from June to October. Contrary to his team’s expectations, there was a lack of genetic diversity, while many samples had many genetic changes in the site called A394V, which is linked to the error-fixing protein.
“We were literally shocked to see the findings,” the researcher told the Japan Times. “The Delta variant in Japan was highly transmissible and [was] keeping other variants out. But as the mutations piled up, we believe it eventually became a faulty virus and it was unable to make copies of itself.”
The theory could be relevant to the previous SARS strain, which was identified in 2003, explaining why it didn’t cause a pandemic. But that would be hard to confirm, since the outbreak ended relatively quickly and didn’t result in the massive collection of genetic data necessary to test the hypothesis.
It’s not clear why Japan had this lucky turn of events, but nothing comparable happened in other East Asian countries like South Korea, where populations are genetically close to that of Japan. Virus mutations similar to those flagged by the scientists have been discovered in at least 24 countries, Inoue said. He and his team plan to publish a paper detailing their findings by the end of November.
Even if the natural extinction theory is confirmed, it is at best a temporary reprieve for the Japanese people. New, more successful strains are likely to eventually find their way into the country, though quarantine measures and immigration control could delay the emergence of new variants in Japan, Inoue believes.
Meanwhile, Tokyo is bracing for a new wave of Covid-19 this winter and is preparing to live with the virus. The government reportedly plans to ease travel restrictions by increasing the number of people it allows to enter the country per day from 3,500 to 5,000.
Japan’s fifth wave of Covid-19 has virtually disappeared so dramatically that some scientists are puzzled as to why it happened. One team suggests the highly infectious Delta strain mutated into extinction on the island nation.
In mid-August, Japan experienced a peak in Covid-19 infections, recording over 23,000 new cases per day. Now the metric is just around 170, with deaths attributed to the disease mostly remaining in single digits this month.
The decline has been attributed by many to high vaccination rates, public acceptance of masks, and other factors, but some researchers say the drop was uniquely significant, compared to other nations with similar conditions.
Ituro Inoue, a geneticist at the National Institute of Genetics, believes that Japan had the good fortune of witnessing the Delta strain mostly rooting out other variants of the SARS-CoV-2 virus before then eradicating itself. He explained his team’s theory to the Japan Times newspaper this week.
For some time now, Inoue and his fellow scientists were researching mutations of SARS-CoV-2 and how they are affected by the protein nsp14, which is crucial for the reproduction of the virus.
RNA viruses, like the one causing Covid-19, tend to have a very high mutation rate, which helps them quickly adapt to changes in the environment. However, this opens the door for a so-called “error catastrophe,” when bad mutations pile up and finally cause the full extinction of a strain. The protein nsp14 appears to offer a form of error proofreading that helps the virus genome to stay below the threshold of the “error catastrophe.”
In the case of Japan’s fifth wave of Covid-19, the Delta variant’s nsp14 failed at this job, Inoue believes, based on the genetic study of specimens collected from June to October. Contrary to his team’s expectations, there was a lack of genetic diversity, while many samples had many genetic changes in the site called A394V, which is linked to the error-fixing protein.
“We were literally shocked to see the findings,” the researcher told the Japan Times. “The Delta variant in Japan was highly transmissible and [was] keeping other variants out. But as the mutations piled up, we believe it eventually became a faulty virus and it was unable to make copies of itself.”
The theory could be relevant to the previous SARS strain, which was identified in 2003, explaining why it didn’t cause a pandemic. But that would be hard to confirm, since the outbreak ended relatively quickly and didn’t result in the massive collection of genetic data necessary to test the hypothesis.
It’s not clear why Japan had this lucky turn of events, but nothing comparable happened in other East Asian countries like South Korea, where populations are genetically close to that of Japan. Virus mutations similar to those flagged by the scientists have been discovered in at least 24 countries, Inoue said. He and his team plan to publish a paper detailing their findings by the end of November.
Even if the natural extinction theory is confirmed, it is at best a temporary reprieve for the Japanese people. New, more successful strains are likely to eventually find their way into the country, though quarantine measures and immigration control could delay the emergence of new variants in Japan, Inoue believes.
Meanwhile, Tokyo is bracing for a new wave of Covid-19 this winter and is preparing to live with the virus. The government reportedly plans to ease travel restrictions by increasing the number of people it allows to enter the country per day from 3,500 to 5,000.
When the PRC decides to move on Taiwan, it is unlikely to move in a manner that makes a US decision on intervention clear cut. Should China decide, initially at least, against a full-scale invasion of that island nation, it could instead opt to try to “win without fighting.” Beijing might do so by using its large, state-controlled fishing fleet to cut smaller Taipei-controlled islands off from Taiwan itself much as the PRC is now massing fishing boats to expand Chinese-controlled seas to press claims on the Japanese Senkakus and Whitsun Reef in Philippine waters. Chinese state-owned fisheries companies – part of the so-called ‘Maritime Militia’ – serve as fronts for PLA intelligence. Using their fleets to operate in a manner somewhere between peace and conflict in the gray zone of contested control around Taiwan would allow Beijing to test whether the US and its allies are willing to help defend the island’s independence without being seen to initiate open conflict.
“The Cipher Brief has become the most popular outlet for former intelligence officers; no media outlet is even a close second to The Cipher Brief in terms of the number of articles published by formers.” – Sept. 2018, Studies in Intelligence, Vol. 62 No.
Access all of The Cipher Brief’s national-security focused expert insight by becoming a Cipher Brief Level I Member .
